CAPR Capricor Therapeutics, Inc. stock chart & analysis
Conviction 0HealthcareScan · Fri, Nov 13, 2026Capricor Therapeutics, Inc. (CAPR) closed at $9.53 (-6.98%) on Nov 13, 2026. Its latest daily candle is a three inside down. Price is above its 50-day and below its 200-day moving average. RSI(14) 57, RS Rating 99, -76.4% from its 52-week high, -67.0% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why CAPR moved
From the StockSetups movers recaps that covered CAPR, newest first. A recap states what was known that day.
- After hours+11.9%
Capricor rose 11.9% to $7.15 after hours on 3.35 million shares, above its 20-day average of 2.7 million. Market cap is $371.5M.
After-Hours Movers Oct 30, 2026: Why INO, CLRO, CAPR Jumped → - Close+58.0%
According to live web research sourced from GuruFocus and StocksToTrade, Capricor's stock surged on an FDA application amendment alongside newly published data in The Lancet and a significant analyst upgrade.
Top Stock Movers Today — August 14, 2026: Why MDXH, CAPR, HTFL, IMXI & UMAC Surged → - Premarket+87.9%
Multiple credible headlines confirm a pair of high-impact events hitting simultaneously. According to GuruFocus, CAPR stock is surging on an FDA application amendment, with the company actively in the regulatory countdown for a key submission.
Premarket Stock Movers — August 14, 2026: Why STKH, CAPR, AKAN, CYCU & SXTC Are Surging →
Financials as of Wed, Sep 30, 2026 · quarterly.
CAPR technical analysis
Trend
CAPR's moving averages are mixed — no clean uptrend or downtrend. It closed 17.6% above the 50-day ($8.10) and 52.5% below the 200-day ($20.04). ADX(14) at 30 points to a strong, established trend. It meets 3 of 8 trend-template criteria.
Momentum
RSI(14) is 57, in the bullish half of its range. The MACD histogram is positive. A bullish MACD divergence is in place. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.
Volume and volatility
Volume on the latest session ran 0.8× its 20-day average. It trades about $32.8M a day on average. ATR(14) is $0.9539, 10.0% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.29) shows accumulation.
Key levels
The 52-week range is $2.96 to $40.37; price is 76.4% below the high and 221.8% above the low. The VWAP anchored at the 52-week high is $14.66, above price.
Performance
CAPR returned +5.8% (1 week), +31.0% (1 month), +27.9% (3 months), -68.0% (6 months), +53.6% (1 year), -67.0% (year to date).
About Capricor Therapeutics, Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Pharmaceutical Preparations · Listed 2002 · 231 employees
Recent news
- CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This MonthStocktwits · Wed, Nov 11, 2026
- Capricor Therapeutics Inc (CAPR) (Q3 2026) Earnings Call Highlights: Deramiocel Nears PDUFA ...Yahoo Finance · Wed, Nov 11, 2026
- Capricor (CAPR) Q3 2026 Earnings Call TranscriptMotley Fool · Tue, Nov 10, 2026
- Capricor Therapeutics Q3 Earnings Call HighlightsMarketbeat · Tue, Nov 10, 2026
- CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final ReviewStocktwits · Tue, Nov 10, 2026
- Capricor: Q3 Earnings SnapshotYahoo Finance · Tue, Nov 10, 2026
- Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance · Tue, Nov 10, 2026
- CAPRICOR THERAPEUTICS, INC.: Earnings resultsSEC EDGAR · Tue, Nov 10, 2026
- CAPR Stock Edges Higher Ahead Of Q3 Earnings, But Retail’s Attention Remains Firmly Fixed On Nov. 22 FDA Decision For DeramiocelStocktwits · Tue, Nov 10, 2026
- CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA DecisionStocktwits · Mon, Nov 9, 2026
Insider activity
SEC Form 4 transactions in CAPR · open-market 4 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Krasney Karen EVP, GENERAL COUNSEL · Common Stock · 2026-06-25 | Sell | 24.1K | $732K | 2026-06-25 | 2026-06-29 |
Krasney Karen EVP, GENERAL COUNSEL · Stock Option (Right to Buy) · 2026-06-25 | Exercise | 24.1K | — | 2026-06-25 | 2026-06-29 |
Krasney Karen EVP, GENERAL COUNSEL · Common Stock · 2026-06-25 | Exercise | 24.1K | $77K | 2026-06-25 | 2026-06-29 |
Bergmann Anthony CHIEF FINANCIAL OFFICER · Common Stock · 2026-06-25 | Exercise | 24.1K | $77K | 2026-06-25 | 2026-06-29 |
Bergmann Anthony CHIEF FINANCIAL OFFICER · Common Stock · 2026-06-25 | Sell | 24.1K | $732K | 2026-06-25 | 2026-06-29 |
Bergmann Anthony CHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) · 2026-06-25 | Exercise | 24.1K | — | 2026-06-25 | 2026-06-29 |
Bergmann Anthony CHIEF FINANCIAL OFFICER · Common Stock · 2026-06-24 | Sell | 400 | $12K | 2026-06-24 | 2026-06-24 |
Krasney Karen EVP, GENERAL COUNSEL · Stock Option (Right to Buy) · 2026-06-24 | Exercise | 400 | — | 2026-06-24 | 2026-06-24 |
Krasney Karen EVP, GENERAL COUNSEL · Common Stock · 2026-06-24 | Sell | 400 | $12K | 2026-06-24 | 2026-06-24 |
Krasney Karen EVP, GENERAL COUNSEL · Common Stock · 2026-06-24 | Exercise | 400 | $1K | 2026-06-24 | 2026-06-24 |
SEC filings
EDGAR filings in CAPR · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.